- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04191226
Genetic Mutation in Recurrent Cervical Cancer
December 18, 2019 updated by: Lei Li
Overall Perspective on the Characteristics of Genetic Mutation in Recurrent Cervical Cancer
Little is known about the characteristics of genetic mutation in recurrent cervical cancer.
This study is to explore the targeted genetic mutations via a multi-gene panel, which consists of more than 500 hundred genes.
The mutation characteristics are to be revealed in single nucleotide variants, copy number variations, insertion-deletion variations, and genomic structural variations.
The total mutation burden (TMB) will be calculated.
The status of microsatellite instability, expression of PD-1 and PD-L1 antibodies are also tested.
These findings will be studies in association with the patients' prognosis and sensitivity to platinum-based chemotherapy and immunotherapy.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
300
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Recruiting
- Lei Li
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
Patients of pathology confirmed of recurrent cervical adenocarcinoma, squamous carcinoma or adenosquamous carcinoma, and aged 18 years or older
Description
Inclusion Criteria:
- Aged 18 years or older
- Pathology confirmed of recurrent cervical adenocarcinoma, squamous carcinoma or adenosquamous carcinoma
- With available materials for analysis
- With detailed clinicopathological information
- Given consent to participate the trial
Exclusion Criteria:
- Not meeting all of the inclusion criteria
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of genetic mutations
Time Frame: Two years
|
Frequency of various genetic mutations among recruited patients
|
Two years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total mutation burden
Time Frame: Two years
|
Total mutation burden calculated in definite patient
|
Two years
|
Frequency of microsatellite Instability
Time Frame: Two years
|
Microsatellite Instability in definite patient
|
Two years
|
Expression rates of PD-1 and PD-L1 antibodies
Time Frame: Two years
|
Expression rates of PD-1 and PD-L1 antibodies among recruited patients
|
Two years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Lei Li, Peking Union Medical College Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 19, 2019
Primary Completion (Anticipated)
January 1, 2022
Study Completion (Anticipated)
January 1, 2023
Study Registration Dates
First Submitted
December 5, 2019
First Submitted That Met QC Criteria
December 5, 2019
First Posted (Actual)
December 9, 2019
Study Record Updates
Last Update Posted (Actual)
December 20, 2019
Last Update Submitted That Met QC Criteria
December 18, 2019
Last Verified
December 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CC-TMB
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Microsatellite Instability
-
Sultan Abdulhamid Han Training and Research Hospital...CompletedColorectal Cancer | Colorectal Carcinoma | Microsatellite Instability Low | Microsatellite Instability High | Microsatellite Instability-HighTurkey
-
Hoffmann-La RocheRecruitingAdvanced Solid TumorsUnited States, Belgium, Spain, Denmark, United Kingdom
-
Sun Yat-sen UniversityGuangdong Provincial Hospital of Traditional Chinese Medicine; Guangdong Provincial...Active, not recruitingColorectal Cancer | Microsatellite Instability HighChina
-
Changhai HospitalRecruitingRectal Cancer | Microsatellite Instability Low | Immunotherapy | Neoadjuvant Chemoradiation TherapyChina
-
LiuYingNot yet recruitingColorectal Cancer | Neoadjuvant Therapy | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)China
-
Sun Yat-sen UniversityRecruitingColorectal Cancer Stage IV | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)China
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruitingColorectal Cancer | Neoadjuvant Therapy | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)China
-
Sun Yat-sen UniversityRecruitingColorectal Cancer | Neoadjuvant Therapy | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)China
-
Sun Yat-sen UniversityThe Second Affiliated Hospital of Kunming Medical UniversityCompletedColorectal Cancer Metastatic | Microsatellite Instability High | Mismatch Repair DeficiencyChina
Clinical Trials on Multi-gene panel testing
-
Lei LiRecruitingEpithelial Ovarian Cancer | Microsatellite Instability | PD-L1 | Nucleotide Variant | Copy Number Variation | Insertion-deletion Variation | Genomic Structural Variation | Total Mutation Burden | PD-1China
-
Invitae CorporationCompleted
-
Invitae CorporationRecruitingCancer | Solid Tumor | Solid Tumor, AdultUnited States
-
Ambry GeneticsBeth Israel Deaconess Medical Center; HonorHealth Research Institute; University...CompletedPancreatic Ductal AdenocarcinomaUnited States
-
Institut CurieCompletedGenetic Predisposition to DiseaseFrance, Germany
-
University of Colorado, DenverRecruitingColorectal NeoplasmUnited States
-
T2 BiosystemsTerminatedLyme DiseaseUnited States
-
Instituto Nacional de Ciencias Medicas y Nutricion...CompletedPancreatic Cancer | Pancreatic AdenocarcinomaMexico
-
Institute of Cancer Research, United KingdomRoyal Marsden NHS Foundation TrustRecruitingProstate Cancer | Genetic PredispositionUnited Kingdom
-
Duke UniversityNational Institute of Allergy and Infectious Diseases (NIAID)Not yet recruitingPneumonia, Bacterial | Ventilator Associated Pneumonia